Jade Biosciences Inc.

Jade Biosciences Inc. is a biotechnology company dedicated to developing innovative therapies for autoimmune diseases. The company’s primary focus is on advancing best-in-class biologic treatments that address critical unmet medical needs in patients suffering from these chronic conditions. Jade’s lead development program, JADE-001, targets the anti-APRIL (A Proliferation-Inducing Ligand) pathway, which is implicated in immunoglobulin A nephropathy (IgAN), a progressive kidney disorder. This candidate is poised to enter first-in-human clinical trials in the second half of 2025, aiming to reduce harmful IgA antibodies and preserve kidney function. In addition to JADE-001, Jade Biosciences maintains a robust preclinical pipeline with two additional antibody discovery programs, JADE-002 and JADE-003, focused on undisclosed targets within immunology. Formed through a recent merger and supported by significant investment from leading healthcare funds, Jade Biosciences is recognized for leveraging assets licensed from Paragon Therapeutics to build a differentiated portfolio. The company occupies a distinctive role in the biopharmaceutical sector, striving to redefine the standard of care for autoimmune disease patients through targeted, novel therapies.